u/foam_head_fred

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

nothing on this board is a substitute for someone who knows your history

perimenopause and this overlap in ways nobody has good data on

That is an accusation about a named individual and it does not belong here in any form.

Correction: that domain is one character different from the one you posted, which is rather the point of this thread.

The group-buy structure, described neutrally, because the arguments here always get personal.

One person collects money, places one order, receives it, splits it and forwards it. That structure concentrates payment, custody and communication in a single point with no contract, no escrow and no recourse designed in. It is not an allegation about any organiser to say so.

What follows from it: the failure mode is silence rather than dispute, the people exposed have no visibility, and there is nothing to escalate to. If you take part, take part knowing the shape of what you have agreed to.

Group buys concentrate custody, payment and communication in one person with no structure behind it. That is not an accusation about anyone — it is a description of the risk shape.

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

the trials were not designed to answer most of the questions asked here

Disagreeing with this line: the absorption question has a product-specific answer and a pharmacist has it.

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.

How long was the randomised phase before any extension?

Does the lot on the vial match the lot on the page?

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

The group-buy structure, described neutrally, because the arguments here always get personal.

One person collects money, places one order, receives it, splits it and forwards it. That structure concentrates payment, custody and communication in a single point with no contract, no escrow and no recourse designed in. It is not an allegation about any organiser to say so.

What follows from it: the failure mode is silence rather than dispute, the people exposed have no visibility, and there is nothing to escalate to. If you take part, take part knowing the shape of what you have agreed to.

Disagree that a lower number is automatically worse. A conservative claim that survives testing is worth more than an optimistic one that does not.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

perimenopause and this overlap in ways nobody has good data on

HPLC-UV and LC-MS answer different questions

Disagree on this specific point. Two honest labs can resolve that impurity differently and report different numbers.

Why the same vial can honestly produce three different numbers.

Purity by area percent is relative to what the detector saw on one gradient at one wavelength. Net peptide content subtracts counterion, water and residual solvent. Mass of peptide per vial is net content times fill weight, and fill weight has its own tolerance.

So a document reading 99% purity, 6% acetate and 4% water is describing a vial that is about 90% peptide by mass, and every one of those numbers is honest. The mistake is treating the headline figure as the answer to "how much peptide did I get".

Why the same vial can honestly produce three different numbers.

Purity by area percent is relative to what the detector saw on one gradient at one wavelength. Net peptide content subtracts counterion, water and residual solvent. Mass of peptide per vial is net content times fill weight, and fill weight has its own tolerance.

So a document reading 99% purity, 6% acetate and 4% water is describing a vial that is about 90% peptide by mass, and every one of those numbers is honest. The mistake is treating the headline figure as the answer to "how much peptide did I get".

the confidence interval is the finding, the point estimate is the headline

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteri

niels_norgaard is right about the programme names. They are different populations with different endpoints.

Not quite. Two labs with different gradients can resolve a close-eluting impurity differently and both be reporting honestly.

Agreed on asking for the storage condition. It is one line and it changes how you read the entire stability claim.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Was in a group buy that went quiet for six weeks. It resolved in the end, but the structure meant I had no visibility and no recourse the whole time.

Did you get the chromatogram or only the summary line?

Batch number and date of analysis, are both on there?

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.

That is a report count, not a test count, and it changes how thin the evidence base actually is.

Group buys concentrate custody, payment and communication in one person with no structure behind it. That is not an accusation about anyone — it is a description of the risk shape.

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

How long was the randomised phase before any extension?

Peptidology gets named here constantly and there is nothing verifiable on file either way

Never name an individual. The sidebar rule exists because the cost of being wrong falls on a person and the benefit of being right falls on nobody in particular.

if the price is impossible, the material is the thing being economised on

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

symptom patterns can track the cycle rather than the dose